The aim was to investigate the outcomes associated with venous thromboembolism (VTE) among irresectable pancreatic cancer patients.
introduction
The strict two-way clinical relationship between cancer and venous thromboembolism (VTE) has been evaluated since Trousseau's time. While subclinical coagulation activation is encountered in up to 90% of cancer patients, only 4% to 15% of them develop VTE [1] . The relationship among cancer, chemotherapy and thrombosis has been more extensively investigated in breast cancer patients. Few data are available for gastrointestinal (GI) cancer patients receiving chemotherapy, in spite of the general perception of a high incidence of thromboembolic complications in patients with mucinous carcinoma of the pancreas and GI tract. A recent retrospective study on patients with different solid tumors found a remarkably high incidence (7%) of VTE in a group of 39 patients with colon cancer during chemotherapy [2] .
Pancreatic carcinoma is currently the fourth biggest leading cause of cancer-related death in the USA. About 10%-15% of patients undergo complete tumor resection and of this proportion fewer than one-fifth are alive 5 years after surgery. In locally advanced or metastatic disease, systemic chemotherapy induces responses in only a few patients. The main clinical benefit of chemotherapy is generally for the palliation of pain and cancer-related symptoms [3] .
Experimental studies in vitro or in animal models support the hypothesis that the inhibition of blood coagulation may interfere with the progression of malignancy. Experimental and clinical data to support the hypothesis that anticoagulation may influence prognosis of cancer patients have been recently reviewed [4, 5] .
There is some evidence that patients with cancer who develop thromboembolism have poorer survival [6, 7] . However most of these studies used population-based data to estimate the incidence and the prognosis of cancer patients, lacking information about performance status and type of treatment, which could influence survival. [8] [9] . In addition we retrieved data from an ongoing GISCAD-sponsored Phase III randomized study comparing gemcitabine with cisplatin and gemcitabine in irresectable pancreatic cancer patients. Also included were 27 patients treated with a Cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) polychemotherapy at the San Raffaele Hospital and not enrolled in the prospective trial previously reported [9] . The study protocols were approved by the local ethical committee and all patients gave informed consent.
Eligibility criteria for inclusion in this study included histological diagnosis of locally advanced unresectable and/or metastatic pancreatic carcinoma, treatment with a gemcitabine-based chemotherapy, an Eastern Cooperative Oncology Group performance status (ECOG-PS) £ 2 and normal hepatic (serum bilirubin < 1.5 mg/dL), renal (serum creatinine < 1.5 mg/dL) and bone marrow (leukocyte count > 4000/lL, platelet count > 100000/lL) functions. Exclusion criteria included prophylaxis with warfarin or low molecular weight heparin (LMWH).
Information on age, gender, histopathology and surgical and medical treatment were retrieved for each patient, as well as on tumor overall response, progression-free survival (PFS) and overall survival (OS). Stage was assessed according to the American Joint Committee on Cancer (Tumour, Node, Metastasis) classification. Tumor response was classified according to World Health Organization criteria.
The medical charts and the radiological history of all patients were checked with regard to ultrasonography of the extremities, chest and abdominal computed tomography (CT) scan and perfusion/ventilation lung scan. In all patients with proven VTE, we actively searched the records and radiological reports for indicators of tumor load at the time of the event. The criterion to diagnose VTE by compression ultrasonography was non-compressibility of a proximal vein. When symptoms suggestive for pulmonary embolism developed, a radionuclide lung scan, a CT scan or both was performed.
statistical methods
All patients satisfying eligibility criteria and treated with at least one cycle of chemotherapy were considered for analysis. Progression-free survival was defined as the time from the beginning of chemotherapy to first appearance of progressive disease or death for any cause; patients known to be alive and without progressive disease at the time of analysis were censored at their last available follow-up assessment.
Overall survival was defined as the time from the beginning of chemotherapy to the date of death from any cause or the date of the last follow-up. Survival curves were estimated using the Kaplan-Meier method. Cox proportional hazards models as implemented in the PHREG program (Statistical Analysis System [SAS] Institute, Cary, NC, USA) were used to estimate and test demographic characteristics and clinical features for their association with PFS and OS. Venous thromboembolism was included both irrespective of the time of occurrence and by distinguishing between occurrence before or during chemotherapy. Overall VTE occurrence was not included in the multivariate models due to multicolinearity problems and because the other two VTE variables were considered more informative.
A proportional hazards model was used for univariate and multivariate analysis. Variables found to be associated with PFS and OS in the univariate analysis (P < 0.10) were considered for the multivariate analysis. A stepwise strategy was then adopted, with a statistical significance cut-off for variable screening of 0.05, and VTE was forced into the model. Results are expressed as hazard ratios (HR) with 95% confidence intervals (CI) reported for each factor. A univariate and multivariate logistic regression model using the same approach was used to assess the effect of the same variables on treatment response, expressing results as odds ratios (OR) and relative 95% CI.
With a total of 210 events in our series, this study had a 95% power of detecting a hazard ratio of at least 2.0 associated with the group with VTE (expected to have a prevalence of about 20% [10] ) with a type I error of 5%, for a bilateral test. The statistically significant level was set at P £ 0.05. Analysis was performed using SAS (Version 9.0) software.
results
A total of 227 consecutive patients were identified and included in the analysis. Demographic and clinical characteristics of the cohort are summarized in Table 1 . Just over half (121, 53.3%) were males and the median age was 66 years, ranging from 38 to 82 years. Forty-four (19.4%) patients had undergone previous surgery, either for curative or palliative intent. Most (63.4%) patients had metastatic disease, while the remaining were classified with locally advanced irresectable disease. Chemotherapy treatment was PEFG for 79 (37.4%) patients; the remaining patients received chemotherapy with gemcitabine or cisplatin and gemcitabine. We excluded five patients who had not received at least one dose of chemotherapy: four patients because of inadequate liver function and one patient because of a concomitant other cancer. Table 2 . At univariate analysis, a significantly higher probability of not responding to treatment was associated with chemotherapy other than PEFG (OR 6.30, 95% CI 3.13-12.68, P < 0.0001), stage IV (OR 1.96, 95% CI 1.10-3.50, P = 0.023), presence of synchronous VTE (OR 2.65, 95% CI 1.34-5.26, P = 0.005) and overall presence of VTE (OR 2.90, 95% CI 1.56-5.40, P < 0.0001). In the stepwise selection model, only chemotherapy treatment other than PEFG (OR 6.38, 95% CI 3.12-13.03, P < 0.0001) and presence of synchronous VTE (OR 3.09, 95% CI 1.40-6.84, P = 0.005) proved to be predictors of progressive disease. No statistically significant effect of occurrence of VTE during chemotherapy on response to treatment was observed either at univariate or at multivariate analysis.
At a median follow-up of 35 months, 211 (93.0%) patients progressed and 210 (92.5%) died. Overall 215 (94.7%) patients progressed or died. In the whole group, the median PFS and OS were 5 and 9.6 months, respectively. At univariate analysis, stage IV (HR 2.05, 95% CI 1.53-2.74, P < 0.0001), presence of synchronous VTE (HR 1.82, 95% CI 1.30-2.54, P = 0.0005), occurrence of VTE during chemotherapy (HR 3.04, 95% CI 2.12-4.36, P < 0.0001) and overall VTE (HR 2.78, 95% CI 2.07-3.72, P < 0.0001) were associated with a shorter PFS, whereas any 5-year increase of age resulted in a lower risk of progression (HR 0.92, 95% CI 0.85-0.99, P = 0.038). Chemotherapy other than PEFG was not significantly associated with PFS (HR 1.30, 95%CI 0.98-1.72, P = 0.064) but was nevertheless included in the multivariate model since the criterion of P < 0.10 for remaining in the model was met. At multivariate assessment, stage IV (HR 1.78, 95% CI 1.32-2.39, P = 0.0002), 5-year age increase (HR 0.92, 95% CI 0.86-0.99, P = 0.044), chemotherapy (HR 1.39, 95% CI 1.03-1.86, P = 0.030) and VTE during chemotherapy (HR 2.62, 95% CI 1.73-3.97, P < 0.0001) reached statistical significance. As for OS, stage IV (HR 1.95, 95% CI 1.46-2.61, P < 0.0001), synchronous VTE (HR 1.45, 95% CI 1.03-2.04, P = 0.031), occurrence of VTE during chemotherapy (HR 1.95, 95% CI 1.32-2.87, P = 0.0008) and overall VTE (HR 1.76, 95% CI 1.30-2.40, P = 0.0003) showed a prognostic negative effect at univariate analysis. In the multivariate model, only the effects of stage (HR 1.95, 95% CI 1.46-2.61, P < 0.0001) and VTE during chemotherapy (HR 1.64, 95% CI 1.04-2.58, P = 0.032) were confirmed to have a prognostic role on survival Table 3 . Figure 1 shows the Kaplan-Meier curves for PFS and OS according to the presence of synchronous VTE and the occurrence of VTE during chemotherapy.
discussion
The most striking finding of this study is that the development of VTE seems to predict a poor prognosis in irresectable pancreatic cancer patients. To our best knowledge this is original article Annals of Oncology the first trial investigating this issue in a homogeneous cohort of patients. Two large population-based studies investigated the prognostic relevance of VTE in cancer patients [6, 7] . However, these studies may have several limitations because they do not give information about chemotherapy or performance status, which may have an impact on overall survival. Chew et al. demonstrated in a population-based study that a diagnosis of thromboembolism at the time of or within 1 year of cancer diagnosis is a significant predictor of death within that year for several cancer types [7] . In our trial patients developing VTE during chemotherapy had a worse prognosis as compared to patients without any thromboembolic event. Our findings in this particular setting extend the results of Sorensen et al., who reported that patients diagnosed concurrently with thromboembolism and cancer had decreased survival compared with a control group of patients (unmatched for stage) who were diagnosed with cancer but without thromboembolism [6] .
In our study, patients developing VTE had a higher probability of developing progression during treatment and a higher progression and mortality rate. There are several biological explanations which support our clinical data. In the last 30 years basic research studies have indicated: (i) that tumor cells possess the capacity to activate blood coagulation by various mechanisms; (ii) that this capacity parallels tumor cell malignant transformation; and (iii) that fibrin formation in tumor tissues, as a final product of the clotting cascade activation, is involved in tumor growth and dissemination. A number of experimental studies in vitro and in animal models support the hypothesis that inhibiting blood coagulation may interfere with the progression of malignancy [11] [12] [13] .
Recently Nitori et al. investigated, in an elegant study, the prognostic significance of tissue factor (TF) in pancreatic ductal carcinoma. In this study increased TF expression was correlated with the extent of the primary tumor, lymph node metastasis, lymphatic distant metastasis, advanced tumor-node metastasis stage and high tumor grade. More importantly, a high TF expression was an independent negative predictor for survival [14] .
In addition to these experimental studies, one may argue that patients with VTE may have more biologically aggressive cancer, have greater underlying comorbidity or simply die earlier because of complications associated with thromboembolism and/or its treatment. However it seems unlikely that complications of venous thromboembolism can account entirely for the increased mortality among the patients in our study who had thromboembolic events. In our retrospective analysis we did not retrieve from medical charts acute death due to pulmonary embolism.
Furthermore, at univariate analysis a significantly higher probability of not responding to treatment was associated with the presence of synchronous VTE (OR 2.65, 95% CI 1.34-5.26, P = 0.005). In the stepwise selection model, this variable proved to be a predictor of progressive disease. Several recent reports have demonstrated that activation of coagulation is strictly related to cell proliferation and resistance to apoptosis, which is one of the most common pathways of action for cytotoxic drugs [15, 16] . Further studies are required to determine the reason that VTE is so strongly associated with a poor prognosis.
The strength of this study is a relatively large cohort of patients, all treated with a gemcitabine-based chemotherapy, 
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currently the most commonly used standard of care. In addition response to treatment, time to progression and overall survival have been collected prospectively. The limitation of our study is that the clinical research for VTE was performed retrospectively. Indeed, only symptomatic VTE could be considered and therefore a number of asymptomatic VTE may have been missed, with a consequent underestimation of the VTE risk. However, the incidence of VTE found in our study did not differ significantly from that reported by other studies. The high incidence of VTE in locally advanced or metastatic pancreatic cancer patients has been reported recently by Blom et al. [17] . The authors calculated incidence rates of venous thrombosis and compared this with population rates using a standardized morbidity ratio. The risk of venous thrombosis was increased 60-fold compared with the general population, at a cumulative risk of nearly 10%. In this study metastatic cancer patients receiving chemotherapy and with a tumor of the corpus or cauda were at highest risk of developing VTE. Appropriately, Blom et al. suggest that for locally advanced or metastatic pancreatic cancer patients receiving chemotherapy the role of primary prophylaxis should be considered, because anticoagulant treatment may prevent serious comorbidity and associated suffering. In previous reports, the incidence of bleeding for cancer patients receiving anticoagulant treatment is markedly lower than the incidence of venous thrombosis in patients with distant metastases [18, 19] . Oral anticoagulation with Vitamin K antagonists (VKA) may be problematic in patients with cancer. Drug interactions, malnutrition and liver dysfunction can lead to wide fluctuations of International Normalized Ratio. In addition cancer patients, compared to non-cancer patients, have a higher rate of VTE recurrence during oral anticoagulant therapy with VKAs; they also show a higher anticoagulation-associated hemorrhagic risk. Results from a recent randomized clinical trial demonstrate that in these patients long-term treatment with LMWH is safe and more effective than treatment with VKAs [20] . It is difficult to compare the incidence of VTE in our study to that in the other large trials evaluating the role of chemotherapy in metastatic pancreatic cancer patients. Indeed, many clinical trials in pancreatic cancer published in recent years have not reported toxic effects related to VTE. original article
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Furthermore, in its initial version the US National Cancer Institute's criteria for common toxicity did not include VTE, suggesting that this type of complication had been underestimated. In a recent retrospective cohort study using the discharge database of the University Health System Consortium, Khorana et al. were able to demonstrate not only that VTE is frequent in hospitalized neutropenic cancer patients, including perceived low-risk subgroups such as patients with hematologic malignancies and non-metastatic disease, but also that it is associated with increased in-hospital mortality [21] . Since venous thrombosis without embolism is not a life-threatening condition, the authors suggest that the presence of venous thrombosis could signify an aggressive tumor biology and therefore a worse short-term prognosis. Although data from other cancers suggest that the development of thrombosis adversely affects cancer-related survival [22, 23] , our study is the first to evaluate this issue in pancreatic cancer patients.
Our patients were treated within clinical trials. As a corollary these patients had a ECOG-PS grade of 2 or less and a relatively basal good prognosis. Recently, two prospective randomized, placebo-controlled trials, specifically evaluating LMWH for survival in cancer patients, have been reported. In both studies the survival of patients with a good prognosis was significantly in favor of LMWH compared with placebo [24, 25] . It may be intriguing that from another point of view our data seem to support these results.
Finally, the University of Rochester (NY, USA) Community Clinical Oncology Program is currently conducting a Phase III study sponsored by the US National Cancer Institute, which randomly assigns patients with locally advanced or metastatic pancreatic cancer to gemcitabine with or without dalteparin once per day (Protocol URCC-U2200, NCT00031837, URCC 5012, NCI-5012, NCI-CCC-99-45, NCI-P02-0212). A second trial assessing the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer, locally advanced pancreatic cancer or non-small-cell lung carcinoma is ongoing (Protocol FRX106365 NCT00312013). These trials will provide important information regarding improvements in survival and incidence of thromboembolic disease from the addition of a LMWH to standard therapy for pancreatic cancer.
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